EIF3B promotes cancer progression in pancreatic cancer

References

• Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet. 2016;388(10039):73–85.
   PubMed Web of Science ®Google Scholar
• Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694–9705.
   PubMed Web of Science ®Google Scholar
• Wolfgang CL, Herman JM, Laheru DA, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63(5):318–348.
   PubMed Web of Science ®Google Scholar
• Rabow MW, Petzel MQB, Adkins SH. Symptom management and palliative care in pancreatic cancer. Cancer J. 2017;23(6):362–373.
   PubMed Web of Science ®Google Scholar
• Garcia G, Odaimi M. Systemic combination chemotherapy in elderly pancreatic cancer: a review. J Gastrointest Cancer. 2017;48(2):121–128.
   PubMed Web of Science ®Google Scholar
• Aslan M, Shahbazi R, Ulubayram K, et al. Targeted therapies for pancreatic cancer and hurdles ahead. Anticancer Res. 2018;38(12):6591–6606.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen Z. Mutation detection and molecular targeted tumor therapies. STEMedicine. 2020;1(1):e11.
   Google Scholar
• Masutani M, Sonenberg N, Yokoyama S, et al. Reconstitution reveals the functional core of mammalian eIF3. Embo J. 2007;26(14):3373–3383.
   PubMed Web of Science ®Google Scholar
• Chai RC, Wang N, Chang YZ, et al. Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma. Cancer Cell Int. 2019;19(1):155.
   PubMed Web of Science ®Google Scholar
• Wang L, Ouyang L. Effects of EIF3B gene downregulation on apoptosis and proliferation of human ovarian cancer SKOV3 and HO-8910 cells. Biomed Pharmacother. 2019;109:831–837.
   PubMed Web of Science ®Google Scholar
• Tian Y, Zhao K, Yuan L, et al. EIF3B correlates with advanced disease stages and poor prognosis, and it promotes proliferation and inhibits apoptosis in non-small cell lung cancer. Cancer Biomark. 2018;23(2):291–300.
   PubMed Web of Science ®Google Scholar
• Choi YJ, Lee YS, Lee HW, et al. Silencing of translation initiation factor eIF3b promotes apoptosis in osteosarcoma cells. Bone Joint Res. 2017;6(3):186–193.
   PubMed Web of Science ®Google Scholar
• Zang Y, Zhang X, Yan L, et al. Eukaryotic translation initiation factor 3b is both a promising prognostic biomarker and a potential therapeutic target for patients with clear cell renal cell carcinoma. J Cancer. 2017;8(15):3049–3061.
   PubMed Web of Science ®Google Scholar
• Xu F, Xu CZ, Gu J, et al. Eukaryotic translation initiation factor 3B accelerates the progression of esophageal squamous cell carcinoma by activating β-catenin signaling pathway . Oncotarget. 2016;7(28):43401–43411.
   PubMedGoogle Scholar
• Wang Z, Chen J, Sun J, et al. RNA interference-mediated silencing of eukaryotic translation initiation factor 3, subunit B (EIF3B) gene expression inhibits proliferation of colon cancer cells. World J Surg Onc. 2012;10(1):119.
   PubMed Web of Science ®Google Scholar
• Liang H, Ding X, Zhou C, et al. Knockdown of eukaryotic translation initiation factors 3B (EIF3B) inhibits proliferation and promotes apoptosis in glioblastoma cells. Neurol Sci. 2012;33(5):1057–1062.
   PubMed Web of Science ®Google Scholar
• Taucher V, Mangge H, Haybaeck J. Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application. Cell Oncol (Dordr)). 2016;39(4):295–318.
   PubMed Web of Science ®Google Scholar
• Spilka R, Ernst C, Mehta AK, et al. Eukaryotic translation initiation factors in cancer development and progression. Cancer Lett. 2013;340(1):9–21.
   PubMed Web of Science ®Google Scholar
• Golob-Schwarzl N, Krassnig S, Toeglhofer AM, et al. New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors. Eur J Cancer. 2017;83:56–70.
   PubMed Web of Science ®Google Scholar
• Spilka R, Ernst C, Bergler H, et al. eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation. Cell Oncol (Dordr). 2014;37(4):253–267.
   PubMed Web of Science ®Google Scholar
• Golob-Schwarzl N, Schweiger C, Koller C, et al. Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6. Oncotarget. 2017;8(60):101224–101243.
   PubMedGoogle Scholar
• Truitt ML, Conn CS, Shi Z, et al. Differential requirements for eIF4E dose in normal development and cancer. Cell. 2015;162(1):59–71.
   PubMed Web of Science ®Google Scholar
• Qu Y, Zhao R, Wang H, et al. Phosphorylated 4EBP1 is associated with tumor progression and poor prognosis in Xp11.2 translocation renal cell carcinoma. Sci Rep. 2016;6:23594
   PubMed Web of Science ®Google Scholar
• Fukuchi-Shimogori T, Ishii I, Kashiwagi K, et al. Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res. 1997;57(22):5041–5044.
   PubMed Web of Science ®Google Scholar
• Wolfe AL, Singh K, Zhong Y, et al. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature. 2014;513(7516):65–70.
   PubMed Web of Science ®Google Scholar
• Joyce CE, Yanez AG, Mori A, et al. Differential regulation of the melanoma proteome by eIF4A1 and eIF4E. Cancer Res. 2017;77(3):613–622.
   PubMed Web of Science ®Google Scholar
• Vaysse C, Philippe C, Martineau Y, et al. Key contribution of eIF4H-mediated translational control in tumor promotion. Oncotarget. 2015;6(37):39924–39940.
   PubMedGoogle Scholar
• Falletta P, Sanchez-Del-Campo L, Chauhan J, et al. Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma. Genes Dev. 2017;31(1):18–33.
   PubMed Web of Science ®Google Scholar
• Carvalho A, Chu J, Meinguet C, et al. A harmine-derived beta-carboline displays anti-cancer effects in vitro by targeting protein synthesis. Eur J Pharmacol. 2017;805:25–35.
   PubMed Web of Science ®Google Scholar
• Grosso S, Volta V, Sala LA, et al. PKCbetaII modulates translation independently from mTOR and through RACK1. Biochem J. 2008;415(1):77–85.
   PubMed Web of Science ®Google Scholar
• Golob-Schwarzl N, Puchas P, Gogg-Kamerer M, et al. New pancreatic cancer biomarkers eIF1, eIF2D, eIF3C and eIF6 play a major role in translational control in ductal adenocarcinoma. Anticancer Res. 2020;40(6):3109–3118.
   PubMed Web of Science ®Google Scholar
• Mangge H, Niedrist T, Renner W, et al. New diagnostic and therapeutic aspects of pancreatic ductal adenocarcinoma. Curr Med Chem. 2017;24(28):3012–3024.
   PubMed Web of Science ®Google Scholar
• van der Post RS, Vogelaar IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52(6):361–374.
   PubMed Web of Science ®Google Scholar
• Li A, Qiu M, Zhou H, et al. PTEN, insulin resistance and cancer. Curr Pharm Des. 2017;23(25):3667–3676.
   PubMed Web of Science ®Google Scholar
• Reiss K, Del Valle L, Lassak A, et al. Nuclear IRS-1 and cancer. J Cell Physiol. 2012;227(8):2992–3000.
   PubMed Web of Science ®Google Scholar
• Cusan M, Mungo G, De Marco Zompit M, et al. Landscape of CDKN1B mutations in luminal breast cancer and other hormone-driven human tumors. Front Endocrinol (Lausanne). 2018;9:393.
   PubMed Web of Science ®Google Scholar